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Background: The aging of the population has led to the increase of chronic diseases, especially dementia and
cardiovascular diseases, and it has become necessary for their relatives to dedicate more time in caregiving.
The objective in the first phase of this study is to evaluate the effectiveness of a Primary Health Care procedure to
increase the physical activity of people with dementia and their relative caregivers. Also the effect on the cognitive
state and cardiovascular risk will be assessed.
Methods/Design: Design: Clinical, multicentric and randomized trial. A simple random sampling to select 134
patients diagnosed with dementia will be carried out. After contacting their relatives, his/her participation in the
trial will be requested. A basal assessment will be made and the participants will be asigned to control or
intervention group (1:1). Variables: The main measure will be the assessment of physical activity (podometer and
7-PAR) in patients and caregivers. In patients with dementia: ADAS-cog, functional degree and cardiovascular risk. In
caregivers: cardiovascular risk, general health and quality of life. Intervention: For 3 months, participants will receive
instructions to do physical activity with an adapted program. This program will be designed and applied by Primary
Health Care professionals in patients with dementia and their caregivers. The control group will receive regular care.
Analysis: An intention-to-treat analysis will be carried out by comparing the observed differences between basal,
6 and 12 months measures. Change in the mean of daily steps assessed with the podometer and 7-PAR will be the
main result.
Discussion: If the main hypothesis is confirmed, it could be useful to improve the cognitive state of patients with
dementia, as well as the cardiovascular risk of all of them. The results can be good to improve technical features of the
devices that register the physical activity in the patients with dementia, and it could facilitate its commercialization.
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Different types of dementia and cardiovascular diseases
(CVD) are the most important health problems in elderly
people. In Spain, ischemic heart disease is the main cause
of losing years of life adjusted by disability in men, while
the main cause in women is dementia [1]. The aging of
the population has led to an increase in chronic diseases
and disabilities. It has become necessary for relatives to
dedicate more time in caregiving, especially women. This
makes it a requirement to incorporate a gender perspective
into the contents of this research about these diseases. For
all these reasons it is important to find strategies to help pa-
tient with dementia (PWD) or with CVD and their relative
caregivers (RC).
Treatment of people with dementia
Nowadays it is recommended to approach the treatment
of dementia with a multifactorial focus that includes both
pharmacological and non-pharmacological interventions
[2]. Pharmacological treatments of PWD principally ad-
dress to cognitive impairment. Cognitive impairment con-
stitutes the most relevant demonstration of dementia and
it’s tend to be associated to different symptoms that affect
the individual’s functional abilities, which interfere with
the habitual activities and reduce their quality of life (QL)
and the QL of their caregivers [3-5]. It has been found that
some drugs can help delaying the development of behav-
ioral symptoms and that these drugs can contribute in a
substantial way to improve the QL of the patients, their
relatives, and their caregivers. But it has also been ob-
served that the administering of antipsychotics in PWD
can increase the mortality and the risk of cerebrovascular
accidents [6]. A recent review [2] concludes that the non-
pharmacological therapies (NPT) can be a useful, versatile
and potentially cost-effective tool to improve clinical dem-
onstrations and the QL of the PWD, as well as the care-
giver. In respect to the cognition results, functionality for
the Basic Activities of Daily Living (BADL), behavior and
mood, the magnitude of the effect achieved with different
NPTs is similar to that observed with the use of drugs.
Due to the widespread absence of secondary effects and
its flexibility to be adapted to individual cases, the NPTs
should be the first choice of therapy to improve the func-
tionality of the BADL or to modify specific behaviors [2,7].
Non-pharmacological therapies: physical activity
Several randomized clinical trials (RCTs) in PWD have
shown that physical activity (PA) is a beneficial interven-
tion for healthy older people, because it may increase the
functional capacity, control for cardiovascular risk factors
and slow the progression of cardiovascular disease [8,9]. It
is emphasized in the reviews on the NPTs in dementia
[2,10], that there is a need to carry out major RCTs in the
area of physical exercise. In various RCTs with PWD, PAseems to provide benefits for the QL, problematic behav-
iors, depression, functionality, and falls [11,12], but they
do not find evidence that it will improve CVD in the long-
term. Nevertheless, recent results are encouraging [13-15]
because they suggest a potentially beneficial relationship
between physical activity and cognitive function, and they
are designing new trials that may help clarify this issue
[16-20]. Baker et al. [21] found that there was improve-
ment in the executive control in sedentary women with
CVD after six months of high intensity aerobic activity.
With the current data, it seems aerobic exercise interven-
tions are more effective than those of stretching [14,16,22].
CVD and dementia are closely related—whether in the
form of Alzheimer’s disease (AD) or CVD—and they share
very similar risk factors [3,23-25]. It’s possible that there
are many mediation mechanisms that improve the CVDin
relation to PA, by improving brain vascular function, cere-
bral perfusion, and the stimulation of synaptogenesis [16].
Reinforcing data from recent years suggests that modifi-
able behavior can have an impact on brain plasticity in hu-
man beings and animals [26]. Although unclear which
mechanisms can influence the deposition of an amyloid, it
is also possible that exercise can have direct relative effects
on the metabolism of glucose and proteins through neuro-
trophic factors, neuroinflammatory factors, and cerebro-
vascular functioning [27]. Therefore those interventions
that are recommended to improve the CVD may be bene-
ficial to improve the cognitive level, such as walking
quickly on flat terrain, at least 30 minutes every day of the
week [3,23]. On the other hand, it is unclear why some
cognitive functions seem to improve with physical exer-
cise, while other functions seem to be insensitive to the
change. This is an aspect that has been challenging to as-
sess since there has been no agreement on the minimum
battery of cognitive tests that must be carried out in order
to detect clinically relevant and transparent changes, and
that allow an increase in the reproducibility of the results
in future investigations [12,19,21,25].
Interventions with people with dementia and with
their caregivers
One limitation of the effectiveness of NPT on PWD is
the difficulty of carrying them out in the real environ-
ment where the PWD and caregivers are [2]. Sometimes
it is only possible to do so in specialized centers and al-
most always is a burden for the caregiver, aggravating the
negative consequences that their own care entails, such as
the deterioration of the mental health, poor social support
and the decrease of leisure time [28]. Of the interventions
offered to CG of patients with dementia, the interventions
are predominately psychosocial [2,29]. One of the recom-
mendations that should be done is to increase the time
they have for themselves, since making pleasant activities
is a proven method to improving one’s mood [30]. It is
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to participate in and to make a detailed list of the activities
that can be increased, noting when they will take place.
Pleasant activities are not only extraordinary activities like
going on vacation to a far away place. They can actually
be performed daily (reading the newspaper, knitting,
talking with a friend on the phone, visiting friends, etc.).
Additionally it is known that one of the disadvantages
that the CG encounters when attempting to carry out
rewarding activities is that it can be impossible to separate
themselves from the patient while they are carrying out
their duties [28]. On the other hand, it has been observed
that it is difficult for some caregivers to make the decision
to carry out pleasant activities when these activities do not
directly affect the improvement of the status of the family
member whom they care for [30]. A consequence of this is
that the CG of PWD, when compared to non-caregivers,
participate in less PA [31], show increased cardiovascular
risk [32], have an increased risk of hypertension [33], and
suffer more frequently from CVD [34,35]. Although these
problems can be associated with the state of chronic stress
related to the care, and the difficulty in expressing emo-
tions [36], there is no doubt that they are closely related to
PA restriction [30,37]. Von Kanel and col. have observed
that caregivers, who reported high levels of PA, had a car-
diovascular risk score similar to non-caregivers with the
same level of PA [38]. These results suggest that if they in-
crease the levels of PA, the CG could decrease their cardio-
vascular risk to that of the non-caregivers. It is therefore
necessary to evaluate the effectiveness of carrying out
interventions that encourage PA for CG of PWD [38]. In
addition to assessing the degree PA of the caregivers, it
seems necessary to develop interventions that specifically
contribute to the increase of their PA. However, it is not
easy to find interventions that have managed to increase
the PA in adults, which thus would make it possible to
reduce the high proportion of sedentary subjects that are
in Spain. It is estimated to be 75% [8]. At the community
level, a Cochrane review in 2008 concluded that there is no
sufficient data to support the hypothesis that the commu-
nity interventions from the multiple components effect-
ively increase the levels of PA of the population [39]. Some
RCTs developed in the field of Primary Health Care have
achieved positive results, but this was only seen with the
help of PA professionals or educators, and the family doc-
tor. There was an increase of 9.7% in PA for the interven-
tion group with the “green prescription” [40]. Other results
have had discrepancies between men and women [41], and
if it appears to be effective in the increasing PA of the
elderly [42]. Within the framework of the European year
2012, the year of active aging and intergenerational solidar-
ity, the HAPPIER study (Healthy Activity &Physical Pro-
grams Innovations in Elderly Residences) was initiated to
be developed in elderly residences. However, there is moreevidence that all patients with chronic illnesses should be
refered to a rehabilitation program that includes an inter-
vention of PA [43]. Since chronic illness is stable, it seems
reasonable that it should be managed in Primary Health
Care and coordinated as a regular practice. The program
has been initiated into the PACE-Lift in UK in order to de-
termine the feasibility and effectiveness of a Primary Health
Care intervention with a pedometer to increase PA among
older patients [44]. Our research program has participated
in the project “Multi-center Evaluation of the Experimental
Promotional Program of Physical Activity” (PEPAF) [8],
from a sample of 5,000 subjects which were selected ran-
domly from the population consultant in Primary Health
Care of six Spanish provinces. The intervention was carried
out in Primary Health Care centers and has been effective
in increasing the level of PA among inactive patients [8].
Controls for PA were increased to 18 minutes per week
[95% 6–31 min/week]; with an increase of the METS/
hour week of 1.3 [95% Cl, 0.4 2.2]. But what is most im-
portant in relation to this new project is that the effect of
the intervention was particularly positive in people older
than 50 years [8], therefore it could be appropriately
applied to the PWD and their CG. On the other hand, in
older adults there seems to be a linear relationship between
the level of activity and health outcomes, not only among
the sedentary, but also among those who walk more than
12,000 steps per day [45]. Our study incorporates a par-
ticular perspective in respect to the gender differences,
since more than 70% of the caregivers are women, these
usually present a greater osteoarthritis, which makes them
less possible to carry out PA [30].
Evaluation of the therapeutic interventions for dementia
There are many difficulties when assessing the effective-
ness of the RCTs done on the PWD, both in general and
for Alzheimer’s Disease. Therefore, both the Food and
Drug Administration (FDA) and the European Medicines
Agency (EMEA) have developed several guides to oversee
RCTs in patients with AD. It should be noted that in RCTs
on Alzheimer’s Disease drugs the Evaluation Scale of
Behavior-Cognitive Section (ADAS-cog) has been used al-
most unanimously as a measure of cognitive performance
[18,46]. It is a test that provides clinically significant infor-
mation, which is well considered on a conceptual and
neuropsychological basis [47]. The use of the ADAS-cog
as a fundamental measure of the cognitive state should be
permitted to draw comparisons with the results from
other NPT or even with the RCTs, taking all this into ac-
count as it has been proposed in recent trials [15,18] and
that is why this measure is proposed for our intervention.
Due to the multidimensional nature of PA, there is no
ideal way to measure PA since it occurs in natural con-
texts in a set of complex leisure and instrumental behav-
iors. These behaviors are conducted at different levels of
Figure 1 Study outline.
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within one day and in different seasons of the year. Also
PA involves different parts of the body that make that the
measure of PA is more effective in some circumstances
than in others. The majority of research for evaluating PA
has been mainly in adolescents. It is necessary to carry out
research that can provide information about the difficul-
ties of measuring PA in PWD. Self-report questionnaires
are the most utilized methods for evaluating PA in re-
search. The simultaneous involvement of the accompany-
ing family member of the PWD during the walks, as well
as the completion of a validated questionnaire (7-PAR),
should provide important information on the possible re-
lationship between the characteristics of PA and PWD. A
very important drawback to evaluating PA in PWD based
upon the tests carried out, is related to the large variability
observed in terms of the dosage (intensity and duration),
modality (aerobic, muscle endurance, etc.) and scope of
preparation (at the home of the patient [13,48], in resi-
dences or in hospital). In order to quantify the exercise dos-
age, it is important to use objective instruments to measure
in this project, such as digital pedometers. On one hand it
is important to know PA habits of the PWD and relatives,
and on the other hand the effects of increasing their PA.
Objectives
The objective of the first phase of this study is to evaluate
the effectiveness of a Primary Health Care intervention to
increase the PA of PWD and their relative caregivers and
to keep the increase of PA for at least one year. The study
will also evaluate if any effect is modified by age, gender,
or participation as a pair. It will also be estimated the ef-
fect of the intervention on the patients in regards to their
cognitive status, anthropometric measures, cardiovascular
risk factors, overall health and quality of life.
Hypothesis
There are studies that suggest that increasing PA in both
PWD and CG seems to provide health benefits in both
groups. However, there are no interventions that have
demonstrated their effectiveness to ensure that both groups
increase their PA.
Since the implementation of the project PEPAF in Pri-
mary Health Care it has been effective in increasing PA in
inactive adults [8], especially among those over 50 years.
We hope to demonstrate that a physical activity program
that is adapted, designed, and applied by Primary Health
Care professionals for patients with dementia and relative
caregivers (predominantly women), is effective in increas-
ing PA by 20% for PWD and their relative caregivers from
Primary Health Care. Since the physical exercise seems to
contribute and improve or slow down the cognitive im-
pairment in PWD, we hope to reduce the ADAS-cog in
PWD by 3 points. Since CVD and dementia are closelyrelated—whether in the form of vascular cognitive impair-
ment or in the form of Alzheimer’s Disease—and they
share similar risk factors, if this program is effective, it
may benefit people with dementia as well as relative care-
givers, since it could help them maintain and improve
their health, in particular the cognitive level of their pa-
tients and the cardiovascular problems of their CG which




Clinical trial, multicenter studies randomized, controlled,
and randomized into two parallel groups.
Subjects
Study population
It will be conducted in the scope of Primary Health Care
in Salamanca. There will be a simple random sampling
from a list of persons who are diagnosed with dementia
that belong to the participating centers. Participating phy-
sicians will confirm the inclusion criteria and the degree
of evolution (GDS-FAST) Global Deterioration Scale of
Reisberg. The study will contact caregivers of selected
patients who meet the criteria for inclusion and they will
be asked to participate in the project (Figure 1). Of those
who accept, a list will be created of patients and relatives
who provide care for the patient, and at least one person
from this list will be selected to participate in the study. If
there is more than one family member who cares for the
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relatives. Those who accept and meet the criteria for
inclusion/exclusion must complete the informed consent
document. Then they will be quoted in order to perform
the initial evaluation in the Research Unit to both the
PWD and the caregiver.
Inclusion Criteria: a) patient with dementia that re-
sides in his/her home address in the area of the Primary
Health Care center. b) Meets common criteria for the
symptomatic diagnosis of dementia DSM-IV confirmed
by the family doctor or neurologist. c) Identification of
the relatives, or friends (not professional caregiver), who
provides most of the care to the PWD. They do not neces-
sarily have to live with the PWD. d) Completion of in-
formed consent on the part of the caregiver (and PWD
when appropriate).
Exclusion Criteria for the patients or the caregivers:
a) mental disorders due to medical illnesses or related to
substances (DSM-IV-TR). b) Advanced stages of dementia
(GDS 6 or 7), c) Delirium. d) Comorbidity that prevents
them from performing the exercise program intervention:
unstable heart disease, bedridden, the need for a walker or
a wheelchair, significant cerebrovascular diseases such as,
bone and muscle disorders, major psychiatric, neurological
or metabolic disturbances. e) Severe clinical events within
the previous 6 months. f) On the waiting list of surgical
interventions or treatments that require a hospital stay, or
predict stays out of the capital for more than 4 weeks dur-
ing the course of the intervention. g) The caregiver dissents
to participate in the trial. h) Participants who submit any
psychological or general medical condition that in the opin-
ion of the investigator may impede the completion of the
questionnaires in the protocol. i) Participants who are tak-
ing part at the time of the start of the study in a clinical trial
or study involving medications. The PWD take medications
that may negatively affect cognitive function: anticholiner-
gics (i.e. amitriptyline), major tranquilizers (antipsychotic
typical and atypical) and anticonvulsants. g) Changes in
the medication for PWD that they can take for cognitive
function (memantine, rivastigmine, donepezil, galantamine)
during the period of intervention.
Sample size
Accepting a 0.05 Alpha risk and a beta risk of 0.2 in a bi-
lateral contrast, it is required to have 67 patients in the
control group and 67 in the intervention group (total:
134), to detect a difference equal to or greater than 600
steps/day (1/2 SD) between the 2 groups. It is assumed
that the common standard deviation is 1200 steps and it
has estimated losses of a 5% follow-up rate.
Variables and measurement instruments
1. Principle Variable of the StudyIt will be an evaluation of PA in the PWD and the
CG, and there will be two measurements used:
1.1. The PA carried out during 7 days by the digital
Pedometer (Omron Hj-321 lay-UPS) will be used
to evaluate the primary endpoint of psychical
activity, which had been previously validated [49].
Piezoelectric sensors use multiple-position sensing
technology. The manufacturer of the pedometer
describes that in this model, an acceleration
waveform is generated from both sensors, and
based on the size and shape of the waveforms, an
algorithm selects the sensor that is used to count
steps. The advantage of having two piezoelectric
sensors in the pedometer is that it is not critical to
position the pedometer perpendicular to the
ground and upright at the hip to obtain accurate
step counts. For example, if the pedometer is at an
angle of 60- or more from the horizontal or at a
slant, the pedometer can still accurately estimate
steps. It features and displays total steps, aerobic
steps, the distance traveled and calories consumed
and it stores the results of the last 7 days. Calories
burned: By measuring the intensity of your activity,
the unit can calculate the amount of calories
burned. Aerobic steps: Aerobic steps are counted
separately when walking more than 60 steps per
minute and more than 10 minutes continuously.
If a rest of less than 1 minute is taken after a
continuous walk of more than 10 minutes, this will
be regarded as part of “a continuous walk”. The
PWD and the CG will wear the pedometer, the
subject will wear the pedometer on the right side
of the waist on an elastic belt for 7 consecutive
days. The initial evaluations will be at 6 months
and 12 months.
1.2. They will complete a PA questionnaire: The PA is
estimated by means of the 7-day Physical Activity
Recall (7-PAR). The 7-PAR is a general measure of
physical activity, which has been recognized as
valid and reliable tool in recent years and is widely
used in epidemiological, clinical and behavior
change studies. It consists of a semi-structured
interview (10-15 minutes) in which participants
provide an estimate of the number of hours
dedicated to physical or occupational activities
requiring at least a moderate effort in the past
seven days. The categories collected are moderate,
vigorous, and very vigorous physical activity. The
amount of time dedicated to each activity is
multiplied by the mean metabolic equivalents
(METs) of each category: light activity 1.5, moderate
4, vigorous 6, and very vigorous 10. The sum of the
products of the hours dedicated to each activity and
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provides an estimation of the kilocalories per
kilogram used per day (kcal*kg-1 * d-1). The dose of
physical exercise will be estimated in METs/hour/
week and active persons were considered as those
doing at least 30 minutes of moderate activity, five
days a week, or at least 20 minutes of vigorous
activity, 3 days a week or 450 MET ·min · wk−1.
Persons not reaching this level of physical activity
were considered sedentary [50].2. Physical Activity Log:
2.1 They will be recorded the PA habits of the
PWD and their relatives: places, schedules,
habitual activities, leisure, instrumental, and
sports activities; the adaptations to climatic and
to seasonal; covered spaces, outdoor; at home or
in institutions. The changes in the family care plan
for increasing the PA. There are explanations on
the possible discrepancies in registration of the
pedometer and the 7-PAR questionnaire.
2.2 Contributions by medical staff and nurses on
the implementation of program centers and on
the degree of hospitality will be recorded to offer
non-pharmacological therapy with the support of
scientific evidence.
2.3 The evidence related to the PWD’s use of
pedometers will be studied: mode of employment,
possible loss, forgetfulness, improper use, etc.3. Patients with Dementia:
3.1. As the primary measure of cognitive performance,
ADAS-Cog will be applied [51,52]. This test is made
up of various scales that assess memory, learning
and recognition, language, visuoconstructive
abilities, ideational praxis, and temporal-spatial
orientation. The score is given based upon error
and the score can range between 0 and 70 points.
Higher scores indicate a greater severity of cognitive
impairment. This test has been important for
measuring outcomes in numerous AD trials.
3.2. Two cognitive screening tests will be also
administered to assess the general cognitive
status: a) Mini-Mental State Examination
(MMSE). This test [53] explores the functions of
temporal-spatial orientation, attention, memory,
language and constructional praxis, with a
maximum score of 30 points. b) The 7-minute
Screen test (7 MS). This test [54] is made up
of four subtests: Benton Temporal Orientation
Test, Enhanced Cued Recall Test, Clock
Drawing Test and Categorical Fluency. It
will evaluate the functions of orientation,
episodic memory, visuoconstructive abilitiesand verbal fluency, usually altered in
Alzheimer’s disease.
3.3. In addition they will be evaluated based upon
the (Reisberg GDS) global deterioration scale, a
scale of dementia (Blessed, Timlison, and Roth,
1968) and the ability to develop basic activities
of daily living (BADL): Barthel Test and
Lawton-Brody Scale.4. Caregivers: it will be evaluated by the Quality of Life
(SF-12), Mental Health (GHQ-12), Family
Functioning (APGAR-F), and Overload (Zarit Brief ).
5. Other variables of the CG and the PWD:
sociodemographic variables (age, sex, education
level, household, number of living children, marital
status and relationship between patients and CG),
anthropometric variables (weight, height, and waist
circumference), blood pressure levels and analytical
(cholesterol, triglycerides, and blood sugar). The
cardiovascular risk (Framingham-D’Agostino) and
the Charlson comorbidity index will be calculated.
Medications taken that may be linked to
cardiovascular disease, cognitive impairment or with
mental illnesses will be logged.
6. Characteristics of the PWD and the CG and the
motivation to increase the PA by means of the Test
Prochaska-Diclemente will be evaluated.
Baseline evaluation and follow-up
The initial information will be collected in the 1st visit:
It’s comprised of 3 groups of assessments (carried out by
different professionals): A) The initial (health) screening:
diagnostic criteria, GDS, dementia (Blessed, Timlison and
Roth, 1968), informed consent, characteristics of care (dur-
ation, intensity, social support), informant questionnaire
(TIN), socio-demographic data, comorbidity. B) Psych-
ology: a) Patient: Mini Mental State Examination, ADAS-
cog, 7-Minute Screen Test. C) Nursing: Cardiovascular
evaluation, anthropometric measures, pedometers. b) The
caregiver: Quality of Life (SF-12), Overload and burden
(Zarit Breve), Mental Health (GHQ-12), Family Function-
ing (APGAR-F). In VISIT 2, after 7 days, the pedometers
and activity log will be collected (7-PAR); It will be con-
firmed to the Principal Investigator that the initial infor-
mation is complete and the pair will be assigned to the
corresponding group (intervention or control (1:1) accord-
ing to the previously maid random sequence. At 6 and
12 months the baseline evaluation will be repeated for both
the CG and PWD. The flow chart (Figure 1) details the
phases and steps in the development of the clinical trial.
Information on the activities carried out, difficulties in
performing them, activity log, etc. will be collected during
the interviews when the pedometer is collected. After the
6 month evaluation, there will be at least one meeting
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with the control group to complete the information about
the development of the program and the proposals that
have been considered more efficient to better record the
PA (use of pedometers, etc.) and, in the intervention group,
contributions are also prompted to increase the PA in their
environment.
Intervention
During the 3 months they will receive instructions to per-
form PA autonomously (walking, preferably in the vicinity
of the place of residence). The intervention will be con-
ducted by a professional from the health center so only
pairs from the intervention group will have knowledge of
the specific recommendations of the AFISDEMYF. There
will be a 15-minute interview each month. This is an
intervention that has demonstrated its effectiveness in the
PEPAF study [8] and adapted, designed, and been imple-
mented by Primary Health Care professionals for demen-
tia patients and their relative caregivers.
Assessing allocation concealment
The researcher who will make the randomization will be
a different researcher to the one making the assessment.
Nursing and psychology professionals whom are not in-
formed about the group that each participant belongs shall
make the evaluation visits. The subjects of both groups
may participate freely in any other activity during the inter-
vention period and will continue to participate in those
that have been previously initiated.
Timeline
In 2013 the ethics committee approved the study, and the
evaluation questionnaires and procedure manuals were
drafted. Recruiting of the pairs and baseline assessments
will take place in 2014. Every pair will be evaluated again
at 6 and 12 months, including the measurements from the
initial phase. Starting from the third quarter in 2014, there
will be meetings held with successive groups of 10–12
caregivers to complete the information on the difficulties
encountered when increasing the PA for the PWD as well
as the caregivers and on the difficulties that are observed
in order to quantify the amount, intensity and duration of
the PA that the PWD performs. In the last stage of the
project, a physical activity program guide will be developed
for patients with dementia and their relative caregivers, and
a technical report on the characteristics and recommenda-
tions for designing pedometers that are adapted to the
PWD with the aim of facilitating their commercialization
and incorporate them into “memory stores”.
Statistical analysis
The analysis will take place using the intent- to-treat (ITT)
The observed improvements will be compared betweenthe basal measurement, at 6 and 12 months for each
subject assigned to the intervention groups with respect to
those assigned to the control group. The size of the effect
will be defined as the change post-treatment in the experi-
mental group less the change post-treatment in the control
group, divided by the standard deviation combined. The
effect of the intervention will be attributable to the dif-
ferences in such improvements in these groups. A 95%
confidence interval will be calculated. Predictor variables
will be analyzed and confounding factors: sex, age, and it
will be estimated the time’s effect on the repeated measure-
ments that were carried out, using mixed linear regression
models, fixed effects (time, intervention, interaction be-
tween time and intervention) and at random. The data was
analyzed using IBM® SPSS® v.20 software.
Quality control
In order to ensure data quality, the professionals in charge
of data collection will receive specific training. Regular ex-
ternal monitoring will then be performed in the six health
centers to verify adequate application of methods, both in
performing the different examinations and collecting the
information.
Methodological limitations
The study follows all the CONSORT recommendations,
but due to the nature of the intervention, the participants
will not be blinded to the intervention. The work carried
out thus far with PWD have not evaluated the modifica-
tions on the PA level for PWD or CG, so the comparison
we have made based on the results obtained in adults or
elderly people. The monitoring of PWD can present spe-
cific difficulties for performing PA, which have not been
detected in studies of other groups. The effectiveness of an
intervention that increases the PA in PWD/CG pairs has
also not been evaluated, which can be particularly import-
ant, although it is not possible to estimate in which of the
two groups (patients or caregivers) there will be a greater
impact from the intervention. In regards to the validation
of the measurements provided by the pedometer, a proven
model of pedometer has been chosen (Omron HJ-321 Tri-
Axial) and since the measurement of the outcome con-
siders the changes to the step count before and after the
intervention by using the same device, the validation is less
conclusive. With respect to secondary outcomes, related
to the changes in the cognitive status and cardiovascular
risk, it would follow-up period exceeding the duration of
the study would be required to obtain clinically relevant
conclusions.
Ethical and legal issues
The Ethics Committee of the University Hospital of
Salamanca (Spain) approved the project on April 11, 2013.
The subjects will be informed of the project’s objectives,
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Prior, they will sign an informed consent in accordance
with the Declaration of Helsinki [55]. None of the mea-
sures present vital risks to the type of subjects that will be
included in the study. The confidentiality of the included
subjects is ensured at all times by the Organic Law of
Data of Personal Nature (15/1999 of 13 December, LOPD)
and under the conditions of the biomedical research of
Law 14/2007.
Discussion
Recent demographic changes have led to the aging of
the population, and thereby to the increase of chronic
diseases and disability, making a greater commitment of
care by family members a requirement. This situation has
particularly impacted women, since they represent more
than 70% of relative caregivers, so it is necessary to in-
corporate a gender perspective in the research content for
these diseases, an objective that occupies a prominent
place in this project.
Dementia and vascular diseases are closely related and
share similar risk factors. There are studies that suggest
that the increase in PA can bring benefits for PWD and
their CG. The recommendation for CG and PWD to par-
ticipate in therapy at the same time is possibly beneficial for
both, and they can receive additional benefits when per-
formed regularly together, than if it is performed separately.
As a non-pharmacological intervention, it has the potential
to be an effective, efficient and accessible strategy that can
be conducted especially in the field of Primary Health Care
and which could be applied even in areas with scarce re-
sources, since the intervention requires a low cost. Respon-
sibility is thus in the hands of institutions that have
sufficient funds to ensure the development of research and
dissemination of the effectiveness of this therapy. The com-
pletion of a validated questionnaire and measure of contrib-
uting pedometers, should provide important information
on the possible relationship between the characteristics of
the PA held (in terms of dose, modality and scope of prep-
aration) and the observed changes. Since it is known that
the availability of pedometers has managed to improve
interventions aimed at increasing PA, it seems advisable to
investigate the characteristics of these devices in this group
in particular. Current expectations of increasing the PWD,
with the raise of PA between leisure activities as well as
therapies, are important incentives that can be offered to
companies of both sectors. These recommendations could
be derived from this study. It is without a doubt that this is
an extraordinary opportunity to apply scientific knowledge
to improve the prevention, diagnosis, and treatment of the
sedentary lifestyle, helping to improve the current health
indicators of cardiovascular disease and dementia.
It is important to know, on one hand, habits of PA of
PWD and their relatives, and on the other hand the effectof increasing their PA. In the third phase the study intends
to evaluate the indirect effects of the program on the
welcoming and establishment of Primary Health Care
Centers. It will try to measure the contribution of the
program on the relatives of PWD and on the medical
and nursing staff (may offer a non-pharmacological ther-
apy with an endorsement of scientific evidence). Others
can identify and take advantage of the project’s strengths
as to develop PA measurement systems in the groups to
which the study adressess and to promote initiatives that
reduce scientific and technical difficulties that are detected
during the development of the same one.
If the main hypothesis of the study is confirmed, the
first international evidence about the effectiveness of the
intervention in Primary Health Care to increase PA in
PWD/CG pairs will be available. Therefore, a specific
guide for PA could be edited and the possibility to
collaborate in validating recommended devices will be
provided, which will allow to obtain additional funding
for the development of new projects. To do so, ‘it will be
madea registry of the intellectual property and a patent-
able study of the developed tool and in collaboration
with a technology company they will begin the proce-
dures through OTRI office. Finally there will be a
contract/agreement with the developer company for its
marketing and generating funds for future joint projects.
The development of the research project will promote
public-private coordination through the coordination of
the Primary Health Care network, which can enhance the
research in the development of technologies to measure
the PA. If the expected results were achieved, the incentive
that enterprises require to invest in this program would
rely on the possibility of being supported by scientific evi-
dence because of the importance of relevant health issues
that present the targeted groups (dementia and cardiovas-
cular diseases) and also having the possibility of introdu-
cing the use of pedometers through the largest health care
network such as Primary Health Care.Trial status
The trial is currently in the recruitment phase.
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